146 related articles for article (PubMed ID: 11978168)
1. Continuous infusion of coagulation factor products.
Stachnik JM; Gabay MP
Ann Pharmacother; 2002 May; 36(5):882-91. PubMed ID: 11978168
[TBL] [Abstract][Full Text] [Related]
2. Continuous infusion of coagulation factors: current opinion.
Batorova A; Martinowitz U
Curr Opin Hematol; 2006 Sep; 13(5):308-15. PubMed ID: 16888434
[TBL] [Abstract][Full Text] [Related]
3. Continuous infusion of coagulation factors.
Batorova A; Martinowitz U
Haemophilia; 2002 May; 8(3):170-7. PubMed ID: 12010406
[TBL] [Abstract][Full Text] [Related]
4. The evidence behind inhibitor treatment with recombinant factor VIIa.
Ludlam CA
Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():13-8. PubMed ID: 12214140
[TBL] [Abstract][Full Text] [Related]
5. The safety of pharmacologic options for the treatment of persons with hemophilia.
Franchini M; Mannucci PM
Expert Opin Drug Saf; 2016 Oct; 15(10):1391-400. PubMed ID: 27367551
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic decision-making in inhibitor patients.
Allen G; Aledort L
Am J Hematol; 2006 Jan; 81(1):71-2. PubMed ID: 16369965
[TBL] [Abstract][Full Text] [Related]
7. Rationale and indications for continuous infusion of antihemophilic factor (factor VIII).
Goldsmith JC
Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S3-6. PubMed ID: 8735789
[TBL] [Abstract][Full Text] [Related]
8. Continuous infusion of coagulation factor concentrates during intensive treatment.
Holme PA; Tjønnfjord GE; Batorova A
Haemophilia; 2018 Jan; 24(1):24-32. PubMed ID: 28873263
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of using recombinant factor VIIa in continuous infusion.
Schulman S; Bech Jensen M; Varon D; Keller N; Gitel S; Horoszowski H; Heim M; Martinowitz U
Thromb Haemost; 1996 Mar; 75(3):432-6. PubMed ID: 8701403
[TBL] [Abstract][Full Text] [Related]
10. Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: safety, monitoring, and cost effectiveness.
Schulman S;
Semin Thromb Hemost; 2000; 26(4):421-4. PubMed ID: 11092218
[TBL] [Abstract][Full Text] [Related]
11. On the treatment of hemorrhage in patients with hemophilia and associated inhibitors.
Tarantino M; Aledort L
Transfusion; 2001 Dec; 41(12):1628-9. PubMed ID: 11778084
[No Abstract] [Full Text] [Related]
12. The continuous infusion of recombinant activated factor VIIa (rFVIIa) in patients with factor VIII inhibitors activates the coagulation and fibrinolytic systems without clinical complications.
Baudo F; Redaelli R; Caimi TM; Mostarda G; Somaini G; de Cataldo F
Thromb Res; 2000 Jul; 99(1):21-4. PubMed ID: 10904100
[TBL] [Abstract][Full Text] [Related]
13. Factor VIII pharmacokinetics: intermittent infusion versus continuous infusion.
Morfini M; Messori A; Longo G
Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S11-4. PubMed ID: 8735791
[TBL] [Abstract][Full Text] [Related]
14. Factors affecting choice of hemostatic agent for the hemophilia patient with an inhibitor antibody.
Monahan PE; Aledort LM;
Am J Hematol; 2004 Dec; 77(4):346-50. PubMed ID: 15558804
[TBL] [Abstract][Full Text] [Related]
15. Recombinant factor VIIa in paediatric bleeding disorders--a 2006 review.
Mathew P; Young G
Haemophilia; 2006 Sep; 12(5):457-72. PubMed ID: 16919075
[TBL] [Abstract][Full Text] [Related]
16. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors.
Abshire T; Kenet G
J Thromb Haemost; 2004 Jun; 2(6):899-909. PubMed ID: 15140125
[TBL] [Abstract][Full Text] [Related]
17. Recombinant infusion therapies indicated for bleeding disorders.
Kauffman J
J Infus Nurs; 2011; 34(1):29-35. PubMed ID: 21239949
[TBL] [Abstract][Full Text] [Related]
18. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
[TBL] [Abstract][Full Text] [Related]
19. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity--a rebuttal.
Makris M; Van Veen JJ
J Thromb Haemost; 2005 Apr; 3(4):818-9; author reply 819. PubMed ID: 15842387
[No Abstract] [Full Text] [Related]
20. Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: what are the costs, what are the benefits?
Siegmund B; Richter H; Pollmann H
Haemophilia; 2005 Nov; 11(6):638-41. PubMed ID: 16236116
[No Abstract] [Full Text] [Related]
[Next] [New Search]
